MORE THAN 35 YEARS OF EXPERIENCE

Neuraxpharm,
your CNS Specialist

Finding solutions for disorders related to the central nervous system.

Scroll to explore

Driving change

Neuraxpharm
Commitment

1 in 4 people in the world will be affected by mental or neurological disorders at some point in their lives. Roughly every family will have at least one afflicted person in the home.

The wellbeing of those suffering from these disorders is at the heart of all we do. They are the center around whom we investigate and create our solutions.

Our drive and commitment have led us into a leadership position in Europe, specializing in high-quality yet affordable pharmaceuticals for the treatment of central nervous system disorders.

We think of the doctors, the pharmacists, the caretakers and the families. We are your expert CNS specialist.

Researching the early detection, prevention and treatment of common CNS disorders

Key research areas

Psychological wellbeing in children

Obsessive compulsive disorder

Health and wellness

Visit our section on Health and wellness and start taking care of yourself

Neuraxpharm
News

As experts in CNS disorders, we bring you the latest news, product launches and innovative initiatives we constantly undertake to always stay ahead of developments in the CNS area.

Neuraxpharm rebrands Laboratorios Lesvi as Neuraxpharm Pharmaceuticals S.L.

The rebranding of this important part of Neuraxpharm’s production capacity to form Neuraxpharm Pharmaceuticals S.L. marks its full integration within the Group.

Neuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital

The transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity.

Minoryx presents positive interim results from NEXUS registration study for leriglitazone

Update on the strategic alliance with Minoryx for leriglitazone: Minoryx presented positive interim results from its NEXUS registration study targeting pediatric ALD patients with cALD.

Neuraxpharm announces the closing of Sanofi products acquisition

Neuraxpharm announces the closing of the acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi.

Neuraxpharm completes its presence in the Benelux

The establishment of Neuraxpharm Belgium will cover Belgium and Luxembourg, providing CNS treatments to more patients across Europe. The team will expand under Dr. Pierre-Hervé Brun.

Neuraxpharm expands into the Netherlands

Neuraxpharm Netherlands will provide differentiated and specialty generics in the Netherlands, a strategically important CNS pharmaceutical market in Europe. The subsidiary will be run by Philipp Pohoralek as Country Manager for Neuraxpharm Netherlands, alongside his current role as Country Manager for Neuraxpharm Germany.

Neuraxpharm Blog

Understand more about psychiatric and neurological disorders. Our team of health care professionals and expert journalists across Europe works to consistently bring you scientifically solid, trustable information to answer your concerns.

Chronic pain

What are the differences between Acute and Chronic Pain

Pain is a complex phenomenon to study, understand and treat. It is a personal experience with a multidimensional character influenced by biological, psychological and social factors. There is a misconception that the difference between acute and chronic pain. When considering pain and time, we could say that there are three types of pain: acute pain, persistent pain and chronic pain.

Alzheimer's

Is Alzheimer’s hereditary?

In 95% of cases, Alzheimer’s disease is the result of a combination of genetic, environmental and lifestyle factors that affect the person over time. The other 5% of cases, defined as early or hereditary Alzheimer’s, usually appear before the age of 65, with more aggressive and/or rapid deterioration, mainly due to mutations in the genes

Alzheimer's

10 first symptoms of Alzheimer’s

Alzheimer’s disease has many faces. Depending on the region that is affected, the symptoms will vary. Just as the manifestation of the first symptoms of Alzheimer’s in a young person (under 65 years of age) is not the same as in a person in their seventies or eighties. Even so, there are common elements that can alert us that something is happening, and we can take measures to delay the appearance of the symptoms of Alzheimer’s disease.

Multiple sclerosis

Cognitive impairment in Multiple Sclerosis: a reality to treat as early as possible

Cognitive impairment has been reported at all phases and all subtypes of multiple sclerosis (MS). The severity and type of cognitive impairment varies among individuals and can be observed both in early and in later stages. We should promote primary prevention of cognitive decline, in part through interventions and healthy lifestyles that promote brain maintenance.

MORE THAN 35 YEARS OF EXPERIENCE

Neuraxpharm, your CNS Specialist

NeuraxpharmCommitment